COVID vaccination immunity short-lived

Vaccine immunity is short-lived

“Immunological studies have documented a steady decline of antibody levels among vaccinated individuals2. Long-term follow-up of vaccine trial participants has revealed a growing risk of breakthrough infection3. And health-care records from countries such as Israel, the United Kingdom and elsewhere all show that COVID-19 vaccines are losing their strength, at least when it comes to keeping a lid on transmissible disease.” – NATURE: COVID VACCINE IMMUNITY IS WANING — HOW MUCH DOES THAT MATTER?

No point vaccinating those who’ve had COVID-19: Cleveland Clinic study suggests.

The study was conducted on 52,238 employees in the Cleveland Clinic. A positive RT-PCR test was considered to define SARS-CoV-2 infection. A participant was considered vaccinated after 14 days of receiving the 2nd vaccine dose. Similarly, a participant who tested positive for SARS-CoV-2 at least 42 days before the vaccination initiation was considered previously infected.

Interestingly, no significant difference in COVID-19 incidence was observed between previously infected and currently unvaccinated participants, previously infected and currently vaccinated participants, and previously uninfected and currently vaccinated participants.

Previous Covid Prevents Delta Infection Better Than Pfizer Shot

People who recovered from a bout of Covid-19 during one of the earlier waves of the pandemic appear to have a lower risk of contracting the delta variant than those who got two doses of the vaccine from Pfizer Inc. and BioNTech SE.

People given both doses of the Pfizer-BioNTech vaccine were almost six-fold more likely to contract a delta infection and seven-fold more likely to have symptomatic disease than those who recovered. 

The largest real-world analysis comparing natural immunity — gained from an earlier infection — to the protection provided by one of the most potent vaccines currently in use showed that reinfections were much less common. The paper from researchers in Israel contrasts with earlier studies, which showed that immunizations offered better protection than an earlier infection, though those studies were not of the delta variant. 

This study demonstrated that natural immunity confers longer lasting and stronger protection against infection, symptomatic disease and hospitalization caused by the Delta variant of SARS-CoV-2, compared to the BNT162b2 two-dose vaccine-induced immunity.” 

Many studies suggest that vaccine antibodies decrease by 50% in 10 weeks post vaccination.

If you had the infection, and you have long-lived, durable, robust immunity, what happens to that immunity if you get the vaccine?

Medrxiv reports:

“We report on humoral immunity from 2 weeks to 6-months post-vaccination in 120 NH residents and 92 ambulatory healthcare worker controls with and without pre-vaccination SARS-CoV-2 infection.

…Anti-spike, anti-RBD and neutralization levels dropped more than 84% over 6 months’ time in all groups irrespective of prior SARS-CoV-2 infection. At 6 months post-vaccine, 70% of the infection-naive NH residents had neutralization titers at or below the lower limit of detection compared to 16% at 2 weeks after full vaccination.”

The vaccine appears to wipe away the immunity gained from surviving the infection.

Israel Prime Minister explains to the public that the vaccinated are the most at risk

Prime Minister of Israel says: “a very important point that the public must understand, and I think that most of the people are not aware of it yet. The most vulnerable population at the moment, in a paradoxical manner – are the ones who received two doses, but not the third dose. Why? Because they walk around feeling like they are protected because they received both doses. They do not understand that the second vaccine has faded against the “Delta” – and must quickly get vaccinated with the third vaccine dose. Therefore, each one of us, including Members of Knesset Gilad Kariv and Itamar Ben-Gvir who are both young – there are many young people (vaccinated) who are seriously ill, including hospitalizations.

References

2. Naaber, P. et al. Lancet Reg. Health Eur. https://doi.org/10.1016/j.lanepe.2021.100208 (2021). Article Google Scholar 

3. Thomas, S. J. et al. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2110345 (2021). Article Google Scholar

MEDRXIV: WANING IMMUNITY OF THE BNT162B2 VACCINE: A NATIONWIDE STUDY FROM ISRAEL
 

MEDRXIV: SIX MONTH SAFETY AND EFFICACY OF THE BNT162B2 MRNA COVID-19 VACCINE

Leave a Reply